跳至主要内容
临床试验/NCT00000690
NCT00000690已完成1 期

Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers

National Institute of Allergy and Infectious Diseases (NIAID)1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
6
试验地点
1

研究概览

简要总结

To evaluate how the drug dextran sulfate (DS) is absorbed by the stomach and intestines when taken by mouth. To evaluate its effect on blood coagulation.

DS has been reported to have anti-HIV activity. However, it is not known how much of the drug is absorbed into the bloodstream and can be used by the body when DS is taken by mouth.

详细描述

DS has been reported to have anti-HIV activity. However, it is not known how much of the drug is absorbed into the bloodstream and can be used by the body when DS is taken by mouth.

On 2nd day of hospitalization, each volunteer receives an oral dose of DS. Over the next 24 hours, 15 blood samples are obtained (from 15 separate needle sticks). On 4th day, each volunteer is given an injection of DS into vein. 18 blood samples are obtained. Blood is withdrawn before the infusion, at the end of the infusion, and 30 and 60 minutes after the infusion. All urine is collected.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Exclusion Criteria
  • •Co-existing Condition:
  • •Volunteers with any of the following are excluded:
  • •Disorders of coagulation or disorders of plasma lipids.
  • •Allergy to dextran sulfate, other sulfates, other dextrans.
  • •Concurrent Medication:
  • •Volunteers who anticipate need for medication during study.
  • •Volunteers with any of the following are excluded:
  • •Disorders of coagulation or disorders of plasma lipids.
  • •Allergy to dextran sulfate, other sulfates, other dextrans.
  • •Prior Medication:
  • •Excluded within 2 weeks of study entry:
  • •Any medication.
  • •Risk Behavior:
  • •Ingestion of alcohol within 48 hours prior to study.
  • •History of recent drug or alcohol abuse.
  • •Disorders of coagulation or disorders of plasma lipids.
  • •Allergy to dextran sulfate, other sulfates, other dextrans.
  • •Volunteers selected are:
  • •In good general health as determined by screening history, physical examination, and laboratory panel within established limits of normal for hospital laboratory.
  • •Consenting volunteers.
  • •Available for 6 days of continuous hospitalization.

排除标准

  • 未提供

研究者

申办方类型
Nih
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Single Dose Pharmacokinetics of Oral Dextran Sulfate... | 临床试验